Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide versus lenalidomide maintenance after autologous stem cell transplant in newly diagnosed multiple myeloma
NL-OMON58681Phase 3Recruiting
- Sponsor
- Celgene Corporation
- Start
- Dec 2024
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Iberdomide maintenance with Lenalidomide maintenance (2 arms). Primary endpoint: Progression-free survival. Started Dec 2024; status: recruiting.
02
Drugs
iberdomidelenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON58681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58681.